Effects of orlistat comprehensive intervention on metabolic syndrome and its components in overweight or obese polycystic ovarian syndrome patients

doi:10.3969/j.issn.1006-7795.2020.04.003

Abstract

Abstract: Objective To investigate the effects of orlistat integrated intervention on metabolic syndrome (MS) components and therapeutic efficiency in overweight or obese polycystic ovarian syndrome (PCOS) patients with MS. Methods Totally 62 cases of overweight or obese PCOS patients with MS who visited the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University from May 2018 to July 2019 were selected and randomly divided into two groups,using drospirenone and ethinylestradiol tablets(Ⅱ) alone as the control group (n=18), orlistat plus drospirenone and ethinylestradiol tablets(Ⅱ) as the observation group (n=44).The changes of MS components, body mass, sex hormones, liver and kidney function and MS therapeutic efficiency were observed before and after different regimens. Results After 3 months of treatment, body weight, waist circumference, hip circumference, body mass index (BMI), luteinizing hormone(LH), estradiol(E2), total testosterone(TT), free testosterone (FT) and low density lipoprotein-cholesterol(LDL-C) of both two groups decreased significantly, while sex hormone-binding globulin(SHBG) and high density lipoprotein-cholesterol (HDL-C) increased significantly (P<0.05). Body weight, BMI, LDL-C and fasting plasma glucose (FPG) decreased more in the observation group than in control group (P<0.05). There was no significant difference in therapeutic efficiency of MS between the two groups after treatment. Conclusion Combinatorial treatment of orlistat with drospirenone and ethinylestradiol tablets(Ⅱ) is better than drospirenone and ethinylestradiol tablets(Ⅱ) alone in reducing body weight, improving abnormal lipid metabolism, lowering blood glucose and other aspects, which provides a basis for the selection of clinical drug treatment plan.

Key words: overweight or obese, polycystic ovary syndrome, metabolic syndrome, orlistat, drospirenone and ethinylestradioltablets(Ⅱ)

CLC Number:

R711

Min Min, Ruan Xiangyan, Wang Husheng, Cheng Jiaojiao, Luo Suiyu, Xu Zhongting, Li Meng, Alfred O. Mueck. Effects of orlistat comprehensive intervention on metabolic syndrome and its components in overweight or obese polycystic ovarian syndrome patients[J]. Journal of Capital Medical University, 2020, 41(4): 514-519.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.04.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I4/514

References 18

[1]	Trikudanathan S. Polycystic ovarian syndrome[J]. Med Clin North Am, 2015,99(1):221-235.
[2]	Peigné M, Dewailly D. Long term complications of polycystic ovary syndrome (PCOS)[J]. Ann Endocrinol (Paris), 2014,75(4):194-199.
[3]	Schnack L L, Romani A M P. The metabolic syndrome and the relevance of nutrients for its onset[J]. Recent Pat Biotechnol, 2017,11(2):101-119.
[4]	Ali A T. Polycystic ovary syndrome and metabolic syndrome[J]. Ceska Gynekol, 2015,80(4):279-289.
[5]	Sherling D H, Perumareddi P, Hennekens C H. Metabolic syndrome[J]. J Cardiovasc Pharmacol Ther, 2017,22(4):365-367.
[6]	Ruan X, Li M, Mueck A O. Why does polycystic ovary syndrome (PCOS) need long-term management?[J]. Curr Pharmaceut Design, 2018, 24(39):4685-4692.
[7]	Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder:significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)[J]. Life Sci, 2019,228:167-175.
[8]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合症中国诊疗指南[J]. 中华妇产科杂志, 2018,53(1):2-6.
[9]	Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod,2004,19(1):41-47.
[10]	中国肥胖问题工作组. 中国成人超重和肥胖症预防与控制指南[J]. 营养学报, 2004,26(1):1-4.
[11]	Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome-a new worldwide definition[J]. Lancet,2005,366(9491):1059-1062.
[12]	张春梅,赵越,乔杰.多囊卵巢综合征合并代谢综合征临床特点及治疗进展[J].中国实用妇科与产科杂志,2016,32(9):915-918.
[13]	Panda S R, Jain M, Jain S, et al. Effect of orlistat versus metformin in various aspects of polycystic ovarian syndrome:a systematic review of randomized control trials[J]. J Obstetr Gynaecol India, 2018, 68(5):336-343.
[14]	Patni N, Quittner C, Garg A. Orlistat therapy for children with type 1 hyperlipoproteinemia:a randomized clinical trial[J]. J Clin Endocrinol Metab, 2018, 103(6):2403-2407.
[15]	Saleh A, ElFayoumi H M,Youns M, et al. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions[J]. Naunyn-Schmiedeberg's Arch Pharmacol, 2019,392(2):165-175.
[16]	Keevil B G, Adaway J. Assessment of free testosterone concentration[J]. J Steroid Biochem Mol Biol, 2019, 190:207-211.
[17]	McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome[J]. Clin Dermatol, 2018,36(1):14-20.
[18]	李宾,姜晓峰.代谢综合征的研究进展[J].国际检验医学杂志,2018,39(24):2996-3001.